Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 1/2016

Open Access 01-01-2016

Guidance for the prevention and treatment of cancer-associated venous thromboembolism

Authors: Alok A. Khorana, Marc Carrier, David A. Garcia, Agnes Y. Y. Lee

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2016

Login to get access

Abstract

Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with emerging changes in incidence, diagnosis and treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. We address a) the appropriate workup to search for occult malignancy in patients with idiopathic VTE, b) identification of high-risk cancer patients for primary thromboprophylaxis, c) the appropriate immediate and long-term treatment for people with cancer diagnosed with acute thromboembolism, d) the appropriate duration of anticoagulation and e) the appropriate treatment strategy in patients with recurrent VTE on anticoagulation. Areas of controversy and future directions in this field are highlighted.
Literature
1.
Khorana AA, McCrae KR (2014) Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 133(Suppl 2):S35–S38PubMedCrossRef
2.
Khorana AA, O’Connell C, Agnelli G, Liebman HA, Lee AY (2012) Incidental venous thromboembolism in oncology patients. J Thromb Haemost 10(12):2602–2604PubMedPubMedCentralCrossRef
3.
Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488PubMedCrossRef
4.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634PubMedCrossRef
5.
Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 5:101–108PubMedPubMedCentralCrossRef
6.
Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6):vi85–92PubMed
7.
Lyman GH, Khorana AA, Kuderer NM et al (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(17):2189–2204PubMedCrossRef
8.
Streiff MB, Bockenstedt PL, Cataland SR et al (2013) Venous thromboembolic disease. J Natl Compr Canc Netw 11(11):1402–1429PubMed
9.
Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA (2008) Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 149(5):323–333PubMedCrossRef
10.
White RH, Chew HK, Zhou H et al (2005) Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 165(15):1782–1787PubMedCrossRef
11.
Iodice S, Gandini S, Lohr M, Lowenfels AB, Maisonneuve P (2008) Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost 6(5):781–788PubMedCrossRef
12.
Prandoni P, Casiglia E, Piccioli A et al (2010) The risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months. J Thromb Haemost 8(5):1126–1127PubMed
13.
Van Doormaal FF, Terpstra W, Van Der Griend R et al (2011) Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 9(1):79–84PubMedCrossRef
14.
Piccioli A, Lensing AW, Prins MH et al (2004) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2(6):884–889PubMedCrossRef
15.
Din M, Otten HM, Piccioli A et al (2005) Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 3(11):2391–2396CrossRef
16.
Langford N, Stansby G, Avital L (2012) The management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE Guideline CG144. Acute Med 11(3):138–142PubMed
17.
Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275PubMedPubMedCentralCrossRef
18.
Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3):173–180PubMedCrossRef
19.
Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280–2285PubMedCrossRef
20.
Cavo M, Zamagni E, Cellini C et al (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100(6):2272–2273PubMedCrossRef
21.
Petrelli F, Cabiddu M, Borgonovo K, Barni S (2012) Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 23(7):1672–1679PubMedCrossRef
22.
Pabinger I, Thaler J, Ay C (2013) Biomarkers for prediction of venous thromboembolism in cancer. Blood 122(12):2011–2018PubMedCrossRef
23.
Agnelli G, Gussoni G, Bianchini C et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943–949PubMedCrossRef
24.
Agnelli G, George DJ, Kakkar AK et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601–609PubMedCrossRef
25.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907PubMedPubMedCentralCrossRef
26.
Ay C, Dunkler D, Marosi C et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377–5382PubMedCrossRef
27.
Di Nisio M, Porreca E, Ferrante N, Otten H-M, Cuccurullo F, Rutjes AWS (2012) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2:CD008500. doi:10.​1002/​14651858.​CD008500.​pub2 PubMed
28.
Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291–292PubMedCrossRef
29.
30.
Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI (2014) Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 127(1):82–86 e81PubMedCrossRef
31.
Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153PubMedCrossRef
32.
Akl EA, Barba M, Rohilla S et al (2008) Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 27(1):21PubMedPubMedCentralCrossRef
33.
Lee AY, Bauersachs R, Janas MS et al (2013) CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 13:284PubMedPubMedCentralCrossRef
34.
Lee AYY, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs Warfarin for treatment of Acute Venous Thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677–686PubMedCrossRef
35.
36.
Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY (2014) Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134(6):1214–1219PubMedCrossRef
37.
38.
Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA (2011) Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 106(2):371–378PubMedCrossRef
39.
Chaturvedi S, Sidana S, Elson P, Khorana AA, McCrae KR (2014) Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One 9(8):e94048PubMedPubMedCentralCrossRef
40.
den Exter PL, Hooijer J, Dekkers OM, Huisman MV (2011) Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29(17):2405–2409CrossRef
41.
Carrier M, Righini M, Le Gal G (2012) Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost 10(8):1486–1490PubMedCrossRef
42.
Singh R, Sousou T, Mohile S, Khorana AA (2010) High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost 8(8):1879–1881PubMedPubMedCentralCrossRef
43.
Ageno W, Squizzato A, Togna A et al (2012) Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost 10(1):158–160PubMedCrossRef
44.
Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY (2009) Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 7(5):760–765PubMedCrossRef
45.
Carrier M, Khorana AA, Zwicker J et al (2013) Management of challenging cases of patients with cancer associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 11(9):1760–1765PubMedCrossRef
46.
Matsuo K, Carter CM, Ahn EH et al (2013) Inferior vena cava filter placement and risk of hematogenous distant metastasis in ovarian cancer. Am J Clin Oncol 36(4):362–367PubMedCrossRef
Metadata
Title
Guidance for the prevention and treatment of cancer-associated venous thromboembolism
Authors
Alok A. Khorana
Marc Carrier
David A. Garcia
Agnes Y. Y. Lee
Publication date
01-01-2016
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2016
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1313-4

Other articles of this Issue 1/2016

Journal of Thrombosis and Thrombolysis 1/2016 Go to the issue

OriginalPaper

Guidance for the prevention and treatment of the post-thrombotic syndrome

OriginalPaper

Guidance for the treatment and prevention of obstetric-associated venous thromboembolism

OriginalPaper

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

OriginalPaper

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism

OriginalPaper

Guidance for the management of venous thrombosis in unusual sites

OriginalPaper

Pharmacology of anticoagulants used in the treatment of venous thromboembolism
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits